Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STEP-MDD: Individualized Therapy for Major Depressive Disorder
NCT03219008Phase 4Unknown
- Sponsor
- Shanghai Mental Health Center
- Start
- Aug 2017
- Primary completion
- Dec 2019
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
A Phase 4 trial of fluoxetine, bupropion, fluvoxamine, lithium, mirtazapine in major depressive disorder (MDD), sponsored by Shanghai Mental Health Center. Status: unknown.
02
Drugs
fluoxetinebupropionfluvoxaminelithiummirtazapine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT03219008.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03219008.